Voors, Adriaan A.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 6,879

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal

Atrial Fibrillation Management and OutcomesClinical practice guidelines implementation

Cited by 6,418

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementClinical practice guidelines implementation

Cited by 5,866

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012

Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 2,644

Sotagliflozin in patients with diabetes and recent worsening heart failure

Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 1,868

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery

Atrial Fibrillation Management and OutcomesClinical practice guidelines implementation

Cited by 1,403

Vericiguat in patients with heart failure and reduced ejection fraction

Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,358

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,123

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 951

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 893

Iron deficiency in chronic heart failure: an international pooled analysis

Klip, I. T., Comin-Colet, J., Voors, A. A., Ponikowski, P., Enjuanes, C., Banasiak, W., Lok, D. J., Rosentryt, P., Torrens, A., Polonski, L., et al. (2013) · American Heart Journal

Erythropoietin and Anemia TreatmentIron Metabolism and Disorders

Cited by 736

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

Cited by 656

Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND

Brouwers, F. P., de Boer, R. A., van der Harst, P., Voors, A. A., Gansevoort, R. T., Bakker, S. J., Hillege, H. L., van Veldhuisen, D. J., & van Gilst, W. H. (2013) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 610

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Mentz, R. J., Kelly, J. P., von Lueder, T. G., Voors, A. A., Lam, C. S. P., Cowie, M. R., Kjeldsen, K., Jankowska, E. A., Atar, D., Butler, J., et al. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 546

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial

Greenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Desai, A. S., Barnard, D., Bouchard, A., Jaski, B., Lyon, A. R., et al. (2016) · The Lancet

Virus-based gene therapy researchHeart Failure Treatment and Management

Cited by 525

Co-Morbidities in Patients with Heart Failure: An Analysis of the European Heart Failure Pilot Survey

van Deursen, V. M., Urso, R., Laroche, C., Damman, K., Dahlström, U., Tavazzi, L., Maggioni, A. P., & Voors, A. A. (2014) · European Journal of Heart Failure

Heart Failure Treatment and ManagementChronic Disease Management Strategies

Cited by 468

Risk stratification for sudden cardiac death: Current status and challenges for the future

Wellens, H. J. J., Schwartz, P. J., Lindemans, F. W., Buxton, A. E., Goldberger, J. J., Hohnloser, S. H., Huikuri, H. V., Kaab, S., La Rovere, M. T., Malik, M., et al. (2014) · European Heart Journal

Cardiac electrophysiology and arrhythmiasCardiovascular Effects of Exercise

Cited by 405

Heart failure with preserved ejection fraction: from mechanisms to therapies

Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 355

. Effects of serelaxin in patients with acute heart failure

Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Pang, P. S., Ponikowski, P., Voors, A. A., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementPregnancy-related medical research

Cited by 282

Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients

Grote Beverborg, N., Klip, I. T., Meijers, W. C., Voors, A. A., Vegter, E. L., van der Wal, H. H., Swinkels, D. W., van Pelt, J., Mulder, A. B., Bulstra, S. K., et al. (2018) · Circulation Heart Failure

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 278

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis

Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017) · Circulation Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 238

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 223

C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study

Voors, A. A., von Haehling, S., Anker, S. D., Hillege, H. L., Struck, J., Hartmann, O., Bergmann, A., Squire, I., van Veldhuisen, D. J., Dickstein, K., et al. (2009) · European Heart Journal

Heart Failure Treatment and ManagementAcute Myocardial Infarction Research

Cited by 222